SS-31 acts at the inner mitochondrial membrane, while MOTS-c is a cell signal linked to energy stress. Their study models and evidence differ.

The two peptides have different targets and different evidence. SS-31 acts at the inner mitochondrial membrane, while MOTS-c acts as a cell signal linked to energy stress.

Both peptides relate to mitochondria, the parts of cells that help make energy. They are not interchangeable, because they have different structures and proposed actions.
SS-31 is also called elamipretide or MTP-131. It is a synthetic, cell-permeable tetrapeptide, meaning it has four linked amino acids and can enter cells. Its sequence is D-Arg-Dmt-Lys-Phe-NH₂, with Dmt referring to a modified form of tyrosine.
SS-31 binds cardiolipin, a fat-like molecule in the inner mitochondrial membrane. This membrane holds parts of the electron transport chain, a group of proteins that helps make ATP, the cell's main energy-carrying molecule.
In cell and animal models, researchers have studied whether SS-31 supports membrane structure, energy production, and the handling of reactive oxygen species. These are reactive molecules made during normal cell activity. An imbalance between them and cell defenses is called oxidative stress.
MOTS-c is a mitochondria-derived peptide, a short protein chain encoded by mitochondrial genetic material. Its 16 amino acids are encoded by the mitochondrial 12S rRNA gene, as reported by Frontiers in Endocrinology.
MOTS-c is linked to AMPK, an enzyme that acts as an energy sensor inside cells. Cell and animal studies suggest that it can affect energy-related cell signals. Researchers also study whether it can move from mitochondria to the cell nucleus during stress, changing how some genes act. This mitochondria-to-nucleus signal is called retrograde signaling.
| Feature | SS-31 | MOTS-c |
|---|---|---|
| Peptide type | Synthetic four-amino-acid peptide | Mitochondria-encoded 16-amino-acid peptide |
| Main proposed target | Cardiolipin in the inner mitochondrial membrane | AMPK-linked cell signaling |
| Common study models | Cells, animals, and human trials | Cells, animals, and studies of the body's own peptide |
| Research focus | Membrane function and energy production | Cell signaling and responses to energy stress |
SS-31 has been tested in cells and animals, as well as in human trials. The models differ, so their results cannot be treated as if they answered the same question.

The phase I/II MMPOWER trial report in Neurology tested elamipretide in 36 people with genetically confirmed primary mitochondrial myopathy. In the six-minute walk test, the trial reported a dose-related increase in walking distance at day five. The highest-dose group walked a mean of 64.5 metres farther, while the placebo group changed by 20.4 metres; that group comparison had a p value of 0.053.
The trial's results provide human evidence about a specific disease group, formulation, and study period. They do not establish that SS-31 works for other conditions, or that it improves every measure of mitochondrial function.
In the United States, an FDA-approved elamipretide product is indicated for Barth syndrome. That approval is specific to its labelled indication and product; it is not a general approval for other mitochondrial disorders, MOTS-c, or research-grade SS-31.
MOTS-c studies include cell and animal models that measure signals linked to AMPK, energy use, and exercise response. A published study reports an 11.9-fold rise in the body's own MOTS-c in skeletal muscle after exercise. It reports that the rise can remain for four hours. These findings concern MOTS-c made within the body, not proof that a supplied peptide will produce the same effect.
Human MOTS-c evidence is much less direct than the elamipretide trial evidence. Measuring the body's own peptide during exercise or in blood can show a pattern, but it cannot prove that a treatment causes a health or performance change.
| Peptide | What the evidence says | What cannot be inferred |
|---|---|---|
| SS-31 (elamipretide) | The MMPOWER trial tested a defined regimen in people with primary mitochondrial myopathy. | A regimen for other conditions, formulations, or research materials. |
| MOTS-c | The human evidence discussed here concerns the body's own peptide, not a treatment schedule for supplied MOTS-c. Cell and animal protocols are model-specific. | A validated human schedule, or that a model protocol is safe or effective in people. |
When comparing protocols, check the formulation, route, amount, frequency, duration, eligibility, monitoring, and outcomes. Differences in these details can limit direct comparison. A study schedule is not personal directions, and one peptide's protocol should not be transferred to the other.
SS-31 fits research questions about cardiolipin, the inner mitochondrial membrane, and energy production. Cell and animal tests can measure oxygen use, ATP levels, membrane potential, and reactive oxygen species. Those tests describe cell processes, but do not by themselves show better function in an animal or person.

MOTS-c fits questions about AMPK signaling and cell responses to energy stress. Studies may measure AMPK activity, related cell signals, or exercise performance in an animal model. A change in one signal does not prove that mitochondrial function improved overall.
For both peptides, the model and test conditions matter. Cell type, animal species, peptide amount, route, study length, and outcome measure can all affect results. A protocol from one study should not be treated as a tested protocol for another model.
In human studies, measures may include walking distance, muscle strength, fatigue scales, or lab markers. Each captures a different outcome. A blood marker alone cannot prove that a tissue's mitochondria work better, and a functional test alone may not identify the cell process behind a change.
No controlled head-to-head study establishes which peptide works better for a shared outcome. Nor is there a controlled study showing that combining SS-31 and MOTS-c brings added benefit.
Their proposed actions may seem complementary, but that does not prove that a combination is more effective or safe. Researchers would need a study designed to test both peptides, with clear controls and measures for each proposed action.
Limited interaction data do not establish that a combination is safe. A sound study would define its formulation, model, route, timing, and outcome measures in advance, then track both intended effects and adverse events.
Peptide identity and purity are different questions. High-performance liquid chromatography (HPLC) separates material into signals that can help estimate purity. Mass spectrometry checks molecular mass and helps confirm identity. Neither test alone proves the amount of peptide in a container.

A certificate of analysis should name the tested lot, method, result, and test date. It should distinguish purity from content, which is the amount of peptide present. Our pages on reading a certificate of analysis and lab testing explain these records and checks.
Independent lab testing can add a separate check, while lot and batch records link each sample to its production and test history. Researchers may also assess endotoxin, a bacterial toxin, and sterility, which checks for living microbes. These tests answer different questions from identity and purity testing. Details of testing and certification belong alongside the lot record.
Storage and handling can affect results. Lyophilised peptides are freeze-dried, and labs should follow validated storage and handling conditions. Reconstitution means mixing a dried sample into a liquid; aliquoting means dividing a sample into smaller portions. Repeated freeze-thaw cycles can harm some peptides, so labs should record handling and storage conditions.
A cold chain keeps a sample within set temperature limits during storage and transit. Temperature data loggers can record conditions, while a temperature excursion means the sample moved outside its set range. Shipping records, customs rules, and import requirements vary by destination. Our notes on cold-chain shipping and shipping information cover those supply steps.
A pre-filled multi-dose pen stores material in a device with a dial for measuring portions. A vial holds material in a small container for lab staff to handle under a study's defined process. Format alone does not establish identity, stability, or suitability for a study. See our explanation of pens and vials for a comparison of the formats.
SS-31 is listed as a synthetic peptide, while MOTS-c belongs to a family of mitochondria-encoded signaling peptides. Researchers should assess each material by its own identity, lot record, test results, storage history, and study needs. These materials are for research use only.
A blood sample may not reflect a signal inside muscle, heart, or another tissue. Researchers can pair blood tests with tissue-specific measures where the study design allows, then report clearly what each sample represents.
No. Exercise-related measurements concern the body's own peptide and may reflect several changes at once. They do not establish the effect of a supplied peptide under different conditions.
It can repeat mass spectrometry to check the expected molecular mass and use HPLC to assess changes in the sample profile. The same methods and clear lot records help make before-and-after results easier to compare.
Not on their own. Species can differ in metabolism, tissue response, and peptide handling, so a result in one animal model needs confirmation in other models before wider claims are made.
Half-life is the time it takes for the measured amount of a substance to fall by half. It does not tell researchers how long a cell response lasts, or whether that response improves a measured function.
There is not enough human treatment evidence to determine whether MOTS-c harms the liver. Findings about the body's own MOTS-c do not establish the safety of a supplied peptide.
The two peptides contrast a membrane-focused peptide with a mitochondria-derived cell signal. SS-31 has human trial data in a defined disease group, while MOTS-c evidence is more heavily based on cell and animal work and measurements of the body's own peptide.
Neither peptide can be called superior from separate studies with different models and outcomes. A useful comparison starts with the target, then checks study type, measured result, material quality, and limits of the evidence.